Michigan Senate Bill SB0405

Michigan 2025-2026 Regular Session

• Introduced: 6/11/25
• Refer: 6/11/25
• Report Pass: 6/26/25
• Refer: 6/26/25
• Report Pass: 7/1/25
• Engrossed: 7/1/25
• Refer: 7/1/25

Caption

Controlled substances: other; definition of governmental agency under the administration of opioid antagonist act; modify. Amends sec. 101 of 2019 PA 39 (MCL 15.671). TIE BAR WITH: SB 404'25

Impact

The passage of SB 405 would result in significant changes to state laws governing emergency responses to overdose situations. By broadening the definition of who qualifies as a governmental agency employee or agent capable of administering opioid antagonists, the legislation intends to enhance the state’s responses to drug overdose incidents. This aligns with the state’s ongoing efforts to mitigate the effects of the opioid epidemic and ensure that more individuals are equipped and authorized to save lives during critical medical emergencies.

Summary

Senate Bill 405 seeks to amend the 'Administration of Opioid Antagonists Act' by modifying the definition of a governmental agency. This bill is aimed at expanding the scope of who can administer opioid antagonists such as naloxone in emergency situations. The modification allows a broader range of individuals associated with governmental agencies to be considered in the context of providing crucial medical assistance during opioid-related overdose scenarios. The bill signifies an important step in addressing public health concerns related to the opioid crisis in Michigan.

Sentiment

Overall, the sentiment surrounding SB 405 seems to be supportive among legislators and public health advocates. Many view it as a positive measure that will improve the state’s readiness to tackle drug overdoses. However, there may be some concerns regarding the implications of increased access and administration of opioid antagonists by a broader range of individuals, which could warrant discussions around training, liability, and appropriate use in emergency settings.

Contention

Notable points of contention include the potential risks associated with a wider pool of individuals administering opioid antagonists and ensuring they receive adequate training. Critics may also express concerns about the burden on governmental agencies to manage and oversee an increased number of opioid response personnel. Therefore, it will be crucial to balance the expanded access with effective training and guidelines to ensure safe and effective use of opioid antagonists.